Kantar Health, New York, NY, USA.
Kantar Health, New York, NY, USA.
Cancer Treat Res Commun. 2021;29:100462. doi: 10.1016/j.ctarc.2021.100462. Epub 2021 Sep 22.
To report the treatment patterns of non-small-cell lung cancer (NSCLC) patients in China based on a survey of physicians (CancerMPact).
117 Chinese physicians from 27 cities in mainland China were recruited for an online survey in October 2020, reporting on how they treat their patients across all disease stages, including histology and relevant biomarkers in advanced or metastatic NSCLC.
Surveyed physicians indicated that almost half of their stage I patients were treated with surgery only. For stage II patients, it is more common to treat with surgery in combination with radiation and/or systemic therapy (44.5%), whereas the use of surgery decreases for stage III patients and the overall use of systemic therapy increases (63.4%-68.8%). Physicians are more likely to use systemic therapy alone for stage IV patients (31.4%). Chosen treatment regimens for stage IV NSCLC varied by histology and biomarkers, and several observed treatment patterns differed from the USA. In China, platinum-based chemotherapy is standard of care for treating stage IV NSCLC patients, unlike the USA, where checkpoint inhibitors are the dominant choice in first-line. Further, Chinese physicians reported prescribing biomarker-targeted agents for one-third or less of their patients with EGFR, ALK, ROS-1, or BRAF driver mutations, compared to 60-95% in the USA.
As treatment options expand in NSCLC in China, physicians face complex decisions for the treatment of their patients. Treatment patterns often vary, including by disease histology and clinically relevant biomarkers. The standard of care for NSCLC in China also differs from the USA.
基于对医生的调查（CancerMPact），报告中国非小细胞肺癌（NSCLC）患者的治疗模式。
2020 年 10 月，从中国大陆 27 个城市招募了 117 名中国医生，进行了一项在线调查，报告他们在所有疾病阶段如何治疗患者，包括晚期或转移性 NSCLC 的组织学和相关生物标志物。
调查医生表示，他们近一半的 I 期患者仅接受手术治疗。对于 II 期患者，更常见的治疗方法是手术联合放疗和/或全身治疗（44.5%），而对于 III 期患者，手术的使用减少，全身治疗的总体使用增加（63.4%-68.8%）。对于 IV 期患者，医生更有可能单独使用全身治疗（31.4%）。IV 期 NSCLC 的选择治疗方案因组织学和生物标志物而异，一些观察到的治疗模式与美国不同。在中国，铂类化疗是治疗 IV 期 NSCLC 患者的标准治疗方法，而在美国，检查点抑制剂是一线治疗的主要选择。此外，与美国 60-95%的比例相比，中国医生报告为三分之一或更少的 EGFR、ALK、ROS-1 或 BRAF 驱动突变患者开具生物标志物靶向药物。
随着中国 NSCLC 治疗选择的增加，医生在为患者治疗方面面临着复杂的决策。治疗模式经常有所不同，包括疾病组织学和临床相关的生物标志物。中国 NSCLC 的标准治疗方法也与美国不同。
